Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Helperby Therapeutics
Helperby Therapeutics
Activities:
Research & Development
X
LinkedIn
Trending Articles
OINDPs: Nosey about recent developments?
OINDPs are a user friendly and efficacious alternative to injectables in several disease areas
Transforming healthcare with patient centricity
In this opinion article, John Kytariolos, Head of Clinical and Scientific Affairs at Adragos Pharma, discusses patient-centric dosage forms, their properties and the impact...
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Compact process thermostat for efficient temperature control in the laboratory
The temperature control system is designed for the accurate temperature control of small research reactors between -40 to +200 °C
AviadoBio expands presence at Canary Wharf
The company has acquired 11,000 sqft of laboratory and office space in Canary Wharf to accommodate the growing team
Upcoming event
Making Pharmaceuticals
23–24 April 2024 | Exhibition | Coventry, UK
See all
Related Content
Research & Development
How can we save medicine from superbug disaster?
Two leading research teams to collaborate on new fast track antibiotic therapies, with an aim to bring new sophisticated combination therapies to market in a much-reduced timescale
Ingredients
Two of the world’s leading research teams to collaborate on new fast track antibiotic therapies
Aiming to bring new sophisticated combination therapies to market in a much reduced timescale
Regulatory
Treatments to solve global antibiotic crisis may reach the market in 2020
Helperby Therapeutics has developed the first sustainable solution to combat all three deadly critical priority pathogens named by World Health Organisation (WHO)<sup>1</sup>
Research & Development
Helperby Therapeutics and Cadila sign antibiotic drug resistance agreement
Cadila will take a new Helperby compound through Phase III trials, approvals and into commercialisation
Subscribe now